GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Forward PE Ratio

ALPMY (Astellas Pharma) Forward PE Ratio : 22.36 (As of Apr. 29, 2025)


View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Forward PE Ratio?

Astellas Pharma's Forward PE Ratio for today is 22.36.

Astellas Pharma's PE Ratio without NRI for today is 51.34.

Astellas Pharma's PE Ratio (TTM) for today is 50.57.


Astellas Pharma Forward PE Ratio Historical Data

The historical data trend for Astellas Pharma's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Forward PE Ratio Chart

Astellas Pharma Annual Data
Trend 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03 2025-03
Forward PE Ratio
17.12 19.34 12.63 12.95 14.22 13.44 22.07

Astellas Pharma Quarterly Data
2018-03 2018-06 2018-09 2018-12 2019-03 2019-06 2019-09 2019-12 2020-03 2020-06 2020-09 2020-12 2021-03 2021-06 2021-09 2021-12 2022-03 2022-06 2022-09 2022-12 2023-03 2023-06 2023-09 2023-12 2024-12 2025-03
Forward PE Ratio 17.12 16.16 17.76 16.34 19.34 14.58 14.64 13.85 12.63 16.31 14.41 12.05 12.95 16.81 15.65 13.70 14.22 18.32 15.97 14.39 13.44 16.69 17.89 11.86 25.45 22.07

Competitive Comparison of Astellas Pharma's Forward PE Ratio

For the Drug Manufacturers - General subindustry, Astellas Pharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Forward PE Ratio falls into.


;
;

Astellas Pharma Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Astellas Pharma  (OTCPK:ALPMY) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Astellas Pharma Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

From GuruFocus